Read about Endologix
in the news

Embrace the evidence.

The Latest:

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

See Release

All News

Archives

Endologix Receives CE Mark Certification under EU MDR for AFX®2 Endovascular AAA System

Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting

Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA

Endologix Names Dr. Matthew Thompson President and CEO

Endologix Initiates Randomized Study of ALTO® Abdominal Stent Graft System